3,334 followers
@theNCI @NCItreatment The avelumab trial leading to approval was published in @TheLancetOncol, with @PaulNghiem as senior author: https://t.co/bYiJEyOxg4
@theNCI @NCItreatment The avelumab trial leading to approval was published in @TheLancetOncol, with @PaulNghiem as senior author: https://t.co/bYiJEyOxg4
Here it is. https://t.co/L1PqPMFzvX https://t.co/U8l8tRi49q
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group,… https://t.co/asTgk1U1ZV
A new avenue for #merkelcellcarcinoma therapy with avelumab (#PD-L1, but only ~30% respond). Small steps. https://t.co/XTUaRYX38g